Company Overview
Cuprina Holdings (Cayman) Limited functions as a biomedical and biotechnology entity dedicated to the development and commercialization of specialized products designed for the management of chronic wounds. Specifically, the company manufactures and distributes a line of medical-grade sterile blowfly larvae bio-dressing products, which are utilized as a biological treatment method within the medical sector. The firm operates within the Healthcare sector, focusing on the Medical Instruments & Supplies industry, a space characterized by high regulatory standards and specialized demand for advanced therapeutic solutions. In terms of scale, the company carries a market capitalization of $8.56M and generates annual revenue of $30,331 while employing 14 individuals. These financial figures indicate that the company is a micro-cap entity with very limited revenue generation relative to its market valuation, suggesting a position that relies heavily on future product development or strategic positioning rather than current profitable operations. The disparity between the high market cap and the minimal revenue highlights a significant premium placed by the market on the company's intellectual property or potential future market share in the chronic wound management space.
Financial Health
The company reports a trailing twelve-month revenue of $30,331 against a net income of $-2,831,603 and an EBITDA of $-2,810,243. The substantial gap between the positive revenue and the deeply negative net income reveals a cost structure where expenses, likely including research and development or operating costs, vastly exceed the minimal revenue stream, resulting in a significant operational loss. Furthermore, the free cash flow stands at $-7,248,589, which indicates a heavy burn rate and a lack of financial flexibility, suggesting the company is currently consuming cash reserves rather than generating liquidity from operations. The gross margin is reported at -69.2%, the operating margin at -8643.0%, and the profit margin at 0.0%, illustrating a severe inability to cover costs relative to sales and a complete lack of profitability in the traditional sense. The company holds $4.17M in cash while carrying $3.14M in debt, resulting in a debt-to-equity ratio of 40.86, which presents a leveraged balance sheet where liabilities are significant relative to shareholder equity despite the cash buffer. The current ratio of 3.58 indicates a strong short-term liquidity position, meaning the company possesses more than three times the current assets necessary to cover its current liabilities in the near term. Return on Equity is -139.1% and Return on Assets is -28.4%, metrics that reveal management is currently destroying shareholder value and failing to generate efficient returns on the capital deployed for assets.
Valuation Assessment
The P/E Ratio (TTM) and Forward P/E are both listed as N/A, reflecting the fact that the company has no positive earnings to value, which implies that traditional earnings-based valuation models are not applicable and that any future earnings trajectory must be built from the current negative baseline. The price-to-book ratio is 1.43, indicating that the market is valuing the company at 1.43 times its book value, a premium that suggests investors are pricing in significant growth potential or asset quality not fully captured on the balance sheet. Additionally, the price-to-sales ratio is 282.38 and the EV/EBITDA is -2.68, alternative metrics that suggest the market is willing to pay an extreme multiple of revenue despite the negative earnings, pointing to a high-risk, high-reward valuation profile often seen in early-stage biotech firms. The stock has traded between a 52-week low of $0.28 and a 52-week high of $9.50, with the current price position requiring specific calculation relative to the range to determine its proximity to recent highs or lows. The Beta is listed as N/A, meaning there is insufficient data to quantify the stock's volatility relative to the broader market, which adds an element of uncertainty regarding how the share price reacts to general market fluctuations.
Growth & Income
The revenue growth year-over-year is -43.9%, while the earnings growth year-over-year is N/A due to the lack of positive earnings history for comparison. The decline in revenue indicates that the company is currently contracting in terms of sales volume or market share, which implies that the business model has not yet achieved a self-sustaining growth cycle. As the company does not pay dividends, with a dividend yield of N/A and a payout ratio of 0.0%, it follows a reinvestment strategy where earnings are theoretically directed back into the business rather than distributed to shareholders, although in this specific case, the company is burning through cash reserves. The overall growth and income profile is characterized by negative revenue expansion, zero dividend income, and a reliance on cash reserves to fund operations in the absence of profitability.